Elicera Therapeutics AB

ELIC · Nasdaq Stockholm · Healthcare

2.85SEK +2.5%last day

Price as of 2 October 2026

The price over the past year, with dividends: −55.6%

Performance

1 month

−0.2%

1 year

−55.6%

3 years, per year

+3.4%

5 years, per year

−12.4%

Largest fall, 3 years

−90.0%

Below the peak now

−66.6%

Volatility, 1 year

77.7%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

2.6

Dividend yield

0.0%

Return on equity

−32.0%

Net margin

−172.2%

Market value

15 m USD

Quality, value and trend

Where Elicera Therapeutics stands against every Nordic stock today. 100 is best.

Quality69

Profitability and a sound balance sheet over time. Better than 69% of Nordic stocks.

Value7

The price measured against earnings, assets and cash flow. Better than 7% of Nordic stocks.

Trend15

The price development over the past year. Better than 15% of Nordic stocks.

Combined14

Quality, value and trend together. Better than 14% of Nordic stocks.

About Elicera Therapeutics

Elicera Therapeutics AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 3 employees.

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in late preclinical evaluation stage for the treatment of brain tumors.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis